Validation of the Japanese disease severity classification and the GAP model in Japanese patients with idiopathic pulmonary fibrosis

Respir Investig. 2016 Sep;54(5):327-33. doi: 10.1016/j.resinv.2016.02.009. Epub 2016 Mar 30.

Abstract

Background: The clinical course of idiopathic pulmonary fibrosis (IPF) shows great inter-individual differences. It is important to standardize the severity classification to accurately evaluate each patient׳s prognosis. In Japan, an original severity classification (the Japanese disease severity classification, JSC) is used. In the United States, the new multidimensional index and staging system (the GAP model) has been proposed. The objective of this study was to evaluate the model performance for the prediction of mortality risk of the JSC and GAP models using a large cohort of Japanese patients with IPF.

Methods: This is a retrospective cohort study including 326 patients with IPF in the Hokkaido prefecture from 2003 to 2007. We obtained the survival curves of each stage of the GAP and JSC models to perform a comparison. In the GAP model, the prognostic value for mortality risk of Japanese patients was also evaluated.

Results: In the JSC, patient prognoses were roughly divided into two groups, mild cases (Stages I and II) and severe cases (Stages III and IV). In the GAP model, there was no significant difference in survival between Stages II and III, and the mortality rates in the patients classified into the GAP Stages I and II were underestimated.

Conclusions: It is difficult to predict accurate prognosis of IPF using the JSC and the GAP models. A re-examination of the variables from the two models is required, as well as an evaluation of the prognostic value to revise the severity classification for Japanese patients with IPF.

Keywords: GAP model; Idiopathic pulmonary fibrosis; Japanese disease severity classification; Validation.

MeSH terms

  • Aged
  • Classification
  • Female
  • Humans
  • Japan
  • Male
  • Models, Theoretical
  • Pulmonary Fibrosis / classification*
  • Pulmonary Fibrosis / mortality
  • Reproducibility of Results
  • Retrospective Studies